2020
DOI: 10.1039/d0ra01484b
|View full text |Cite
|
Sign up to set email alerts
|

Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug design

Abstract: Understanding the evolution of antibiotic resistance at the molecular level as a functional tool for bioinformatic-based drug design.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
33
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(39 citation statements)
references
References 121 publications
0
33
0
Order By: Relevance
“…Some countries may report data from national surveillance systems with broad population coverage, and others may report data from a subset of local laboratories, clinics, and healthcare settings focusing on one area and limiting the representativeness of data on the national level [ 55 ]. As the validity of surveillance systems relies on the comparability of participating laboratories [ 180 ], each may have different trends of AMR surveillance and different level of capacity for identifying the microorganisms and may show differences in the applied methodology and quality assurance limiting benchmarking [ 55 , 181 , 182 ]. Other inconsistencies across participating laboratories include differences in sampling, the use of different clinical case definitions, and the heterogeneous healthcare utilization [ 181 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Some countries may report data from national surveillance systems with broad population coverage, and others may report data from a subset of local laboratories, clinics, and healthcare settings focusing on one area and limiting the representativeness of data on the national level [ 55 ]. As the validity of surveillance systems relies on the comparability of participating laboratories [ 180 ], each may have different trends of AMR surveillance and different level of capacity for identifying the microorganisms and may show differences in the applied methodology and quality assurance limiting benchmarking [ 55 , 181 , 182 ]. Other inconsistencies across participating laboratories include differences in sampling, the use of different clinical case definitions, and the heterogeneous healthcare utilization [ 181 ].…”
Section: Discussionmentioning
confidence: 99%
“…As the validity of surveillance systems relies on the comparability of participating laboratories [ 180 ], each may have different trends of AMR surveillance and different level of capacity for identifying the microorganisms and may show differences in the applied methodology and quality assurance limiting benchmarking [ 55 , 181 , 182 ]. Other inconsistencies across participating laboratories include differences in sampling, the use of different clinical case definitions, and the heterogeneous healthcare utilization [ 181 ]. Standardization of data management is the most challenging task if health information technology and adequate training are lacking.…”
Section: Discussionmentioning
confidence: 99%
“…Results showed the most isolated bacteria which has multi‫ـ‬antibiotics, resistance is P. aeruginosa and followed by S. aureus, E.coli and Proteus vulgaris. this either could belong to their ability to acquire the genes that responsible for drug resistance from other bacteria in the environment though plasmid or other vector by conjugation or any methods of gene transfer, or belong to ability of Gram negative bacteria especially P. aeruginosa to form biofilm that protect bacteria from the effect of host immunity and antibiotics [24][25][26] . P. aeruginosa is one of the most important pathogens causing different infections such as bacteremia and burn infection [27] .…”
Section: Discussionmentioning
confidence: 99%
“…Annually, around a quarter of all registered deaths across the world are caused by viruses, bacteria and fungi [ 8 , 9 ]. The above-mentioned problems necessitate a rational approach to the design of a new generation of antibiotics [ 10 ].…”
Section: Introductionmentioning
confidence: 99%